The Wall Street Journal reported that weight-loss drugs are reshaping how Americans eat, posing what it called Big Food’s biggest challenge: a shrinking appetite for packaged food itself. Roughly 12% to 14% of U.S. adults now take GLP-1 drugs like Ozempic, Wegovy, or Mounjaro, and households with a GLP-1 user cut grocery spending by an estimated 5.5% in their first six months on the medication while consuming roughly 21% fewer calories on average, according to industry research cited in coverage of the trend.
Conagra Brands, Inc. (NYSE:CAG), maker of Healthy Choice, Birds Eye, and Slim Jim, became the first major food brand to label products “GLP-1 friendly,” adding the tag to more than two dozen high-protein, high-fiber Healthy Choice frozen meals, and a company spokesperson said those items are selling faster than competing products making similar claims. The push comes as Conagra navigates real financial strain: fiscal fourth-quarter 2026 results showed a $1.62 billion net loss driven by a $1.96 billion non-cash goodwill and brand impairment charge, a 50% dividend cut to $0.70 per share annualized, and new CEO John Brase guiding fiscal 2027 organic sales down 1% to 3% with operating margin falling to 10% to 10.5% from roughly 16% a few years ago.
Bull Case
Conagra Brands, Inc. (NYSE:CAG) has gained an early advantage from targeting consumers who use GLP-1 drugs. Healthy Choice became the first major food brand to label products “GLP-1 friendly,” and management says those products already outsell rival products with similar claims. That early traction shows the strategy can generate more than marketing attention.
Conagra is also supporting its GLP-1 strategy with overall operational changes. Project Catalyst targets organizational simplification. The company plans to increase brand-building investment by 14%, or about $40 million, and direct extra capital toward supply chain modernization and in-sourcing. These investments give Conagra a plan to improve its business alongside the product push.
The headline loss makes Conagra’s quarter look worse than its underlying performance. The company reported a $1.62 billion net loss, but a $1.96 billion non-cash goodwill and brand impairment charge drove almost all of the loss. The write-down did not create a comparable cash outflow or directly show the company’s operating performance.
Cutting Conagra’s dividend gives management more financial flexibility. Halving the payout frees roughly $335 million in annual cash, which management plans to direct toward paying down debt, building brands, and modernizing the supply chain. This shift equips Conagra with more resources to fund its turnaround while reducing its overall debt load.
Bear Case
Conagra Brands, Inc. (NYSE:CAG) pivots its marketing strategy as its core business continues to deteriorate. Management expects organic sales to decline 1% to 3% in fiscal 2027 and adjusted operating margin to fall to 10% to 10.5%. Those figures show that Conagra still faces a difficult operating environment even as it pursues its turnaround.
GLP-1 use creates a structural threat since more consumers use these drugs and reduce their calorie intake and grocery spending. So Conagra could face persistent pressure on food volumes. The business therefore needs its GLP-1-friendly products to offset a demand shift that threatens its traditional portfolio.
Conagra’s basic results also remain weak even after excluding the impairment charge. Full-year adjusted EPS fell 25.2% to $1.72, while high cost inflation, including tariffs, keeps pressure on margins. Hence, Conagra faces pressure from both weaker demand and higher costs rather than from GLP-1 adoption alone.
Conagra’s first-mover advantage could fade as major rivals pursue the same consumer shift. Nestlé, Danone, General Mills and Coca-Cola are all reformulating products or marketing toward consumers using GLP-1 drugs. As competitors launch their own offerings, Conagra could lose the differentiation it gained by moving first.
Hedge Fund Data
Insider Monkey’s database shows Conagra was held by 43 hedge funds in the second quarter of 2026, up slightly from 41 in the first quarter, with holdings value rising to $985.2 million from $896.7 million, alongside a notably high 15.3% ownership concentration. General Mills, a packaged-food peer also adapting to GLP-1 trends, was held by 46 funds, up from 44, though its holdings value slipped to $972.3 million from $1.07 billion. The two companies now draw nearly identical hedge fund dollar interest despite Conagra’s much smaller market size.
Conclusion
Conagra’s early move into GLP-1-friendly foods and its operational changes give the company a clear path to adapt to shifting consumer habits. Still, falling demand, higher costs, and growing competition could weaken that strategy’s impact.
Investors should watch whether Conagra can convert its early GLP-1 positioning and cost savings into lasting growth and higher profits.
READ NEXT: Meta’s $18 Billion Teen Safety Deal Puts the Pressure on TikTok and YouTube Next and Tesla (TSLA) Rolls Out its Safety Numbers ahead of a Make-or-Break EU Vote.
